It was great spending time with pharma colleagues who have similar issues and challenges.
Jennifer MerrickInteractive Marketing Manager
Roche
- Why oncology market access models must evolve
The proliferation of stakeholders makes oncology market access increasingly complex—and successful models increasingly essential. Peter Mansell reports.
9:59am, 7th Sep 2010 - Comprehensive strategies for market access
Alan Crofts outlines the flexible market access strategies needed to address the needs of clinical and non-clinical decision makers.
9:51am, 7th Sep 2010 - Market access: Risk sharing and alternative pricing schemes
Shared-risk agreements can represent uncertain rewards for drug makers and payers. What you need to know before entering into one.
2:33pm, 10th Aug 2010
Who Should Attend
Market Access
is the buzz word of the year so far and i am sure it affects you in one way or the other. The conference aim is to provide a platform and open up the discussion to all of you facing similar problems. Things don't need to be harder than they already are. Find out how other people in same roles and teams are overcoming the hurdles you are facing.This year's Market Access Summit will have something on the agenda for:
VPs, heads, directors and managers of:
- Market Access
Pricing & Reimbursement
Health Economics
Pharmacoeconomics
- Comparative effectiveness
Health policy
- Regulatory Affairs
- Commercial and Brand Strategy
- Business Development
Medical Affairs
- Marketing
- (Inter)national Commissioning
Health Technology Assessment
and all those involved in Market Access from across the world.
The event will involve the usual high level delegate status eyeforpharma events are so popular for, in a nice business casual environment to enhance networking and the so important exchange of ideas.
